Lungpacer Medical enrolled the first patient in AERO-PAS, the post-approval study of its AeroPace system, the company said on November 12. California Pacific Medical Center in San Francisco, part of Sutter Health, is the first site.

AERO-PAS is prospective, single-arm and multicenter, with up to 120 adults and enrollment expected to finish in 2028 (NCT07477054). AeroPace won premarket approval under P240012 on December 4, 2024, for improving weaning success in adults who have been on mechanical ventilation for at least 96 hours and have not yet weaned.

The system threads a catheter into a central vein and stimulates the phrenic nerves so the diaphragm keeps working while the ventilator runs. Nothing is surgically implanted, and the device is not for patients who already carry an implantable electronic device. Post-approval study conditions are the part of a PMA that outlasts the approval announcement, and two years between the decision date and a first enrollment is a useful benchmark for anyone modeling their own PMA timeline.